<DOC>
	<DOCNO>NCT01218685</DOCNO>
	<brief_summary>The objective study describe safety immunogenicity non-adjuvanted vaccine pandemic influenza A ( H1N1 ) patient chronic immunocompromised disease , elderly pregnants . The primary immunological endpoint analyze proportion subject antibody titer 1:40 hemagglutination-inhibition assay 21 day 1 dose vaccine . Volunteers monitor safety 21 day vaccination . Volunteers recruit base inclusion exclusion criterion . Vaccine composition : 15 microgram split inactivate virus ( A/California/7/2009 ( H1N1 ) ( NYMC X179A ) . The hypothesis study vaccine safe immunogenic volunteer recruit .</brief_summary>
	<brief_title>Evaluation Pandemic Influenza A ( H1N1 ) Vaccine Chronic Immunocompromised Patients , Elderly Pregnants</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Volunteers able understand agree participate study . Have egg allergy Have past history allergy seasonal influenza vaccine Have receive another inactivated vaccine within prior 2 week live vaccine past four week his/her participation study Acute infectious disease seven day prior vaccination Confirmed prior infection pandemic influenza A ( H1N1 ) Have participate another clinical trial last 6 month Any condition identify principal investigator consider safe enrollment volunteer .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Immunocompromised patient</keyword>
	<keyword>Safety pandemic influenza A ( H1N1 ) vaccine</keyword>
	<keyword>Immunogenicity pandemic influenza A ( H1N1 ) vaccine</keyword>
</DOC>